Xenon製藥 XENE 深 滬
等待開盤 08-10 09:30:00 美东时间
63.36
-1.190
-1.84%
華盛通- 最 高64.49
- 今 開63.00
- 成交量 72.02万股
- 最 低 62.63
- 昨 收 64.55
- 總市值 612.47万
- 52周最高 72.66
- 市盈率 靜 --
- 換手率 0.75%
- 52周最低 35.60
- 委 比 -38.46%
- 總股本 9.67万
- 歷史最高 72.66
- 量 比 1.21
- 振 幅 2.88%
- 歷史最低 2.10
- 每 手 1
- 風險率 9.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $81
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $82 to $81.
08-08 04:27
财报速睇 | Xenon制药 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损1.11亿美元，同比亏损扩大30.6%
华盛资讯8月7日讯，Xenon制药公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损1.11亿美元，同比亏损扩大30.6%。
08-07 07:43
财报速睇 | Xenon制药 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损1.11亿美元，同比亏损扩大30.7%
华盛资讯8月7日讯，Xenon制药公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损1.11亿美元，同比亏损扩大30.7%。
08-07 06:40
Xenon advances azetukalner toward planned U.S. NDA filing
An update from Xenon ( ($XENE) ) is now available. Xenon Pharmaceuticals report...
08-07 04:50
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to 11 new non-officer employees, totaling 32,758 share options and 19,013 restricted share units (RSUs). These grants, approved by the Compensation Committee, were made under Nasdaq Listing Rule 5635(c)(4) to induce employment. The share options have an exercise price of $64.19 per common share, vesting over four years, with 25% vesting on the one-year anniversary of the employee’s sta...
07-31 20:01
Xenon to Report Q2 2026 Financial Results on August 6, 2026
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced it will report its second quarter 2026 financial results and provide a business update on Thursday, August 6, 2026, after U.S. markets close. The presentation will be webcast live at 4:30pm ET (1:30pm PT) and available for replay. Xenon, a neuroscience-focused biopharmaceutical company, is advancing azetukalner, a Phase 3 K<sub>V</sub>7 potassium channel opener for epilepsy, MDD, and BPD, along ...
07-30 20:01
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vancouver and Boston-based Xenon Pharmaceuticals Inc. granted equity inducements to four new employees on July 1, 2026, including 20,200 share options and 11,850 restricted share units (RSUs). The share options have an exercise price of $60.30 per share, vesting over four years, with 25% vesting annually and the remainder vesting monthly. RSUs vest 25% annually over four years. Both are subject to the 2025 Inducement Equity Incentive Plan. Xenon ...
07-02 20:01
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
Biohaven Ltd. (NYSE:BHVN) shares fell Monday after Bank of America Securities (BofA) downgraded the biotechnology company, citing an unfavorable risk-reward profile ahead of a key late-stage epilepsy trial. BofA analyst Dina Ramadane downgraded Biohaven to Underperform from Neutral and lowered the p...
06-30 02:04
Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint
Praxis Precision Medicines reports mixed Phase 2/3 POWER1 results for vormatrigine, with higher-dose data showing stronger seizure reduction.
06-02 18:09
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to 10 new employees, including 32,750 share options and 19,200 RSUs, approved by the Compensation Committee on May 28, 2026. The share options have an exercise price of $54.79, vesting over four years, with 25% after one year and monthly thereafter. RSUs vest 25% annually over four years. Both grants are subject to the 2025 Inducement Equity Incentive Plan. Xenon focuses on developing ...
05-29 20:01
